Open AccessThe APOE ε4 genotype modulates CSF YKL‐40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2
Author(s) -
Gispert Juan Domingo,
Monté Gemma C.,
SuárezCalvet Marc,
Falcon Carles,
Tucholka Alan,
Rojas Santiago,
Rami Lorena,
SánchezValle Raquel,
Lladó Albert,
Kleinberger Gernot,
Haass Christian,
Molinuevo José Luis
Publication year - 2016
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1016/j.dadm.2016.12.002
Subject(s) - apolipoprotein e , cerebrospinal fluid , neuroinflammation , biomarker , dementia , psychology , magnetic resonance imaging , medicine , imaging biomarker , white matter , neuroimaging , disease , pathology , neuroscience , endocrinology , biology , biochemistry , radiology
Among other metabolic functions, the apolipoprotein E (APOE) plays a crucial role in neuroinflammation. We aimed at assessing whether APOE ε4 modulates levels of glial cerebrospinal fluid (CSF) biomarkers and their structural cerebral correlates along the continuum of Alzheimer's disease (AD). Methods Brain magnetic resonance imaging (MRI) scans were acquired in 110 participants (49 control; 19 preclinical; 27 mild cognitive impairment [MCI] due to AD; 15 mild AD dementia) and CSF concentrations of YKL‐40 and sTREM2 were determined. Differences in CSF biomarker concentrations and interactions in their association with gray‐matter volume according to APOE ε4 status were sought after. Results Preclinical and MCI carriers showed higher YKL‐40 levels. There was a significant interaction in the association between YKL‐40 levels and gray‐matter volume according to ε4 status. No similar effects could be detected for sTREM2 levels. Discussion Our findings are indicative of an increased astroglial activation in APOE ε4 carriers while both groups displayed similar levels of CSF AD core biomarkers.